ANCOVA of Change from Baseline Glucose (mmol/L) at Week 24
LOCF
Efficacy Analysis Population

| | Baseline | | Week 24 | | Change from Baseline | | |
|---|---|---|---|---|---|---|---|
| Treatment | N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | LS Mean (95% CI)[a] |
| Placebo | 79 | 5.7 ( 2.23) | 57 | 5.7 ( 1.83) | 57 | -0.1 ( 2.68) | 0.07 (-0.27, 0.41) |
| Xanomeline Low Dose | 79 | 5.4 ( 0.95) | 26 | 5.7 ( 1.26) | 26 | 0.2 ( 0.82) | -0.11 (-0.45, 0.23) |
| Xanomeline High Dose | 74 | 5.4 ( 1.37) | 30 | 6.0 ( 1.92) | 30 | 0.5 ( 1.94) | 0.40 ( 0.05, 0.75) |

[a]Based on an ANCOVA model after adjusting baseline value. LOCF approach is used to impute missing values.
ANCOVA = Analysis of Covariance, LOCF = Last Observation Carried Forward
CI = Confidence Interval, LS = Least Squares, SD = Standard Deviation